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Abstract
Background: Despite considerable reductions in malaria achieved by scaling-up long-lasting insecticidal nets (LLINs) and
indoor residual spraying (IRS), maintaining sustained community protection remains operationally challenging. Increasing
insecticide resistance also threatens to jeopardize the future of both strategies. Non-pyrethroid insecticidetreated wall
lining (ITWL) may represent an alternate or complementary control method and a potential tool to manage insecticide
resistance. To date no study has demonstrated whether ITWL can reduce malaria transmission nor provide additional
protection beyond the current best practice of universal coverage (UC) of LLINs and prompt case management.
Methods/design: A two-arm cluster randomized controlled trial will be conducted in rural Tanzania to assess whether
non-pyrethroid ITWL and UC of LLINs provide added protection against malaria infection in children, compared to UC
of LLINs alone. Stratified randomization based on malaria prevalence will be used to select 22 village clusters per arm.
All 44 clusters will receive LLINs and half will also have ITWL installed on interior house walls. Study children, aged
6 months to 11 years old, will be enrolled from each cluster and followed monthly to estimate cumulative incidence
of malaria parasitaemia (primary endpoint), time to first malaria episode and prevalence of anaemia before and after
intervention. Entomological inoculation rate will be estimated using indoor CDC light traps and outdoor tent traps followed
by detection of Anopheles gambiae species, sporozoite infection, insecticide resistance and blood meal source. ITWL
bioefficacy and durability will be monitored using WHO cone bioassays and household surveys, respectively. Social and
cultural factors influencing community and household ITWL acceptability will be explored through focus-group discussions
and in-depth interviews. Cost-effectiveness, compared between study arms, will be estimated per malaria case averted.
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Discussion: This protocol describes the large-scale evaluation of a novel vector control product, designed to overcome
some of the known limitations of existing methods. If ITWL is proven to be effective and durable under field conditions,
it may warrant consideration for programmatic implementation, particularly in areas with long transmission seasons and
where pyrethroid-resistant vectors predominate. Trial findings will provide crucial information for policy makers in
Tanzania and other malaria-endemic countries to guide resource allocations for future control efforts.
Trial registration: NCT02533336 registered on 13 July 2014.
Keywords: Insecticide-treated wall lining, Long-lasting insecticidal nets, Malaria control, Cluster randomized
controlled trial, Entomological inoculation rate, Insecticide resistance management
Background
Recent, massive scale-up of longlasting insecticidal net
(LLINs) delivery and indoor residual spraying (IRS) has re-
sulted in considerable progress in malaria control across
sub-Saharan Africa [1, 2]. While both interventions can
significantly reduce malaria burden when used alone [3, 4]
or in combination [5], maintaining year-round or longer-
term community protection remains operationally chal-
lenging. Hot dry seasons often deter net usage [6–8] and
routine household damage may compromise the protective
efficacy of LLINs despite their insecticidal longevity [9, 10].
The residual activities of current insecticides approved for
IRS range from 3 to 12 months [11], rendering it logistically
demanding and economically unsustainable in many en-
demic regions [12]. Furthermore, increasing mosquito in-
secticide resistance threatens to jeopardize the longterm
effectiveness of both strategies [13–15].
Insecticidetreated wall lining (ITWL) may represent an
alternate or complementary method of vector control and
a potential tool to manage insecticide resistance. The cur-
rently available product consists of a highdensity polypro-
pylene fabric impregnated with a proprietary mixture of
two classes of nonpyrethroid insecticides, which are de-
signed to migrate differentially to sustain bioefficacy for a
minimum of 3 years. This material can be fixed to the
inner walls of houses and function as a longlasting insecti-
cidal reservoir. It is anticipated that ITWL will act in a
similar manner to IRS, by reducing the longevity of indoor
resting mosquitoes and overall vector population density
(‘mass population effect’), if applied at high community-
level coverage. Theoretically, ITWL could mitigate some of
the limitations of existing control strategies. Once installed,
household protection would be passive and not contingent
on nightly behavioral compliance, unlike LLINs, and the
longer lifespan of ITWL may circumvent the costs associ-
ated with repeated rounds of IRS, particularly in settings
with year round transmission [16].
Initial studies of ITWL using insecticide-treated plastic
sheeting (ITPS) demonstrated high mosquito mortality
and reductions in malaria incidence in temporary labour
shelters and refugee camps [17–20]. Subsequent, experi-
mental hut trials of both pyrethroid and non-pyrethroid
ITPS compared with LLINs have presented more
equivocal results, which have been attributed to varying
levels of insecticide resistance among vector popula-
tions [21–27]. The only community-level trial to evalu-
ate carbamate-treated ITPS in combination with LLINs
in an area of pyrethroid resistance in Benin reported no
additional protection against malaria, potentially due to
limited wall coverage and residual activity of the carba-
mate applied [28].
To date, existing data to support bioefficacy, feasibility
and household acceptability of commercial pyrethroid
ITWL are limited to small-scale trials conducted by the
manufacturer and associates [29–32]. No controlled study
has yet demonstrated that non-pyrethroid ITWL can re-
duce malaria burden nor provide additional protection
beyond the current best practice of universal coverage
(UC) of LLINs and prompt artemisinin combination
therapy (ACT). Here we describe the study design and
methodology of a two-armed cluster randomized con-
trolled trial to evaluate the effectiveness of ITWL and
UC of LLINs compared to UC of LLINs alone, on inci-
dence of malaria infection among children in a rural
area of Tanzania.
Study objectives
Primary objective
To assess the effectiveness of ITWL + LLINs compared to
LLINs alone, on cumulative incidence of malaria parasit-
aemia (asymptomatic and symptomatic) in children aged
6 months to 11 years old.
Secondary objectives
Epidemiological
 To assess the effectiveness of ITWL + LLINs
compared to LLINs alone, on time to first
episode of malaria (asymptomatic and
symptomatic) in children aged 6 months to
11 years old.
 To assess the effectiveness of ITWL + LLINs
compared to LLINs alone, on mean haemoglobin
concentration in children aged 6 to 59 months old.
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Entomological
 To assess the effectiveness of ITWL + LLINs
compared to LLINs alone, on the entomological
inoculation rate (EIR) of host seeking malaria
vectors collected indoors and outside.
 To assess the effectiveness of ITWL + LLINs
compared to LLINs alone, on the relative abundance
of outdoor host-seeking Anopheles gambiae sensu
lato and to measure any changes in indoor and
outdoor biting.
 To assess the effectiveness of ITWL + LLINs
compared to LLINs alone, on host feeding
preferences of An. gambiae s. l.
 To compare changes in levels of insecticide
resistance among An. gambiae s. l. populations in
response to the use of two non-pyrethroid insecti-
cides in ITWL + LLINs compared to LLINs alone.
 To monitor ITWL durability and insecticide
bioavailability over a 12 month period.
Household acceptability
 To identify social, cultural and other factors that
may affect acceptability of ITWL compared to
LLINs in the study area.
 To assess perceptions regarding the implementation
of ITWL among household members, community
leaders, health workers and ITWL installers.
Socio-economic
 To estimate the incremental effectiveness of ITWL
across the entire age spectrum.
 To determine the cost-effectiveness of ITWL in
combination with other malaria control interven-
tions (LLINs or IRS).
Methods/design
Study area and participant recruitment
The study site is situated in Muheza District, Tanga Re-
gion of northeastern Tanzania (5° S, 39° E), encompassing
an area of approximately 4922 km2, ranging from a coastal
plain at sea level to the Usambara Mountains at 1500 m.
The climate is tropical with dense rainforest cover over
the mountain region. Muheza District has four adminis-
trative divisions comprising 33 wards with 135 villages,
mainly inhabited by subsistence farmers. The population
of Muheza District was 204,461 residents in 2012 with an
annual growth rate of 2.2 %; average household size was
4.3 individuals [33]. Across 60 villages, selected as candi-
date study clusters, a baseline survey conducted in January
2014, enumerated 92,692 individuals living in 23,977
households, with most homes constructed from mud or
cement with palm thatch or metal roofs.
In Muheza, malaria transmission occurs throughout the
year with two seasonal peaks following the long rainy sea-
son from July to August and the short rainy season from
December to January. The main malaria vector species are
An. gambiae sensu stricto, An. arabiensis and An. funestus
[34, 35]; Culex quinquefasciatus is also abundant in the
area [36, 37]. Significant resistance of local An. gambiae s.
l. to pyrethroid insecticides (deltamethrin, lambdacyhalo-
thrin and permethrin) has recently been reported and is
expected to spread across this region [38, 39]. Historically,
Muheza District has not been subjected to IRS but did
receive LLINs from the nationwide UC campaign in
2011–12 and the under 5 campaign which preceded it
[40]. During baseline surveys in 2014, household LLIN
coverage was 83 %; 80 % of participants reported sleeping
under a net the previous night. Mean malaria prevalence
was estimated to range between 22 and 25 % after the
short and long rains, respectively, and was significantly
higher among children aged 5–14 years old, compared to
those <5 years old (38 % vs. 18 % and 39 % vs. 34 % after
the short and long rains, respectively).
Villages or groups of neighbouring villages that have
>125 children aged 6 months to 11 years old will be se-
lected to form study clusters. Adjacent clusters will be
≥2 km apart to reduce mosquito contamination between
study arms and maximize potential community effect of
the interventions (Fig. 1). Other selection criteria include
willingness to participate, road accessibility, proximity to
the Muheza District hospital, the National Institute of
Medical Research (NIMR) laboratory and insectary facil-
ities of Amani Medical Research Centre and with no other
ongoing malaria interventions at time of recruitment. Each
cluster will consist of a central ‘core’ area where the study
outcomes will be measured and a surrounding ‘buffer’ area
of approximately 1 km (minimum of 2 km between adja-
cent core areas) where the same interventions will be im-
plemented but no surveys undertaken. It is expected that
each cluster will contain a minimum of 275 households
and each core area will have a minimum of 124 house-
holds. It is assumed that each household will have approxi-
mately one child aged between 6 months to 11 years.
The study cohort of village children aged 6 months to
11 years old, who live in core cluster areas, will be enrolled
to assess the effectiveness of the interventions on malaria
parasitaemia (asymptomatic and symptomatic), the preva-
lence of anaemia and the costs associated with malaria in-
fection and treatment. One hundred and ten children per
cluster will be randomly selected and followed monthly for
1 year after intervention. No distinctions will be made re-
garding gender, ethnic group, medical condition or phys-
ical health. For households with multiple, eligible children,
all potential participants will be recruited. Children will
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only be included in the cohort provided their parents/
guardians give witnessed informed written consent or in
the case of older children, personal assent is obtained. If
consent is not provided then replacement children will be
randomly selected from those remaining in the cluster. As-
surance will be sought from parents/guardians that their
child will remain resident in the village throughout the
study year. Participants and households are free to with-
draw from the study at any time with impunity.
Design
A parallel cluster randomized controlled study design
will be used as ITWL is a community-level intervention
and a village cluster is a suitable unit for randomization.
The study monitoring period will be 12 months, begin-
ning December 2015, which will encompass one long
(February-May, 2016) and one short rainy season (Octo-
ber–December, 2016) and two intervening dry seasons
(Table 1). Following household enumeration, baseline
socio-demographic, economic and household construc-
tion data will be collected. At study onset, all participat-
ing households will be provided with UC of LLINs,
defined as one LLIN per every two persons. Clusters will
then be randomized into two equal groups; all house-
holds in villages from one group will receive ITWL in-
stalled on interior house walls.
To assess whether ITWL and UC of LLINs combined
provide more protection against malaria in children
than LLINs alone, a cohort of children aged 6 months
to 11 years old from cluster cores will be followed
monthly over 1 year. Malaria infection will be detected
by malaria rapid diagnostic test (mRDT; One Step Mal-
aria HRP-II (P.f ) and pLDH (Pan) Antigen Rapid Test,
Standard Diagnostics Inc., Korea) and positive children
will be treated according to national guidelines. This
cohort will also be surveyed for moderate (haemoglobin
7–8 g/dl) to severe anaemia (haemoglobin <7 g/dl) at
enrollment, 6 months and 1 year post-intervention.
Exposure to malaria vectors will be measured indoors
using Centers for Disease Control and Prevention (CDC)
miniature light traps every month in eight randomly se-
lected household in 12 study clusters/arm and outdoors
using Furvela tent traps bi-monthly, in five randomly se-
lected clusters/arm. Mosquito collections will be identified
to species level and analyzed for sporozoite infection, kdr
mutation status and blood meal source. ITWL bioefficacy
will be monitored using WHO cone and cylinder bioas-
says and durability via High Performance Liquid Chroma-
tography (HPLC) analysis and observational household
surveys at three, six and 12 months post-intervention.
Household and community acceptability of ITWLs
and LLINs will be evaluated in a series of focus group
discussions (FGDs), in-depth interviews (IDIs), informal
Fig. 1 Map showing 60 candidate study clusters identified in Muheza District, including core (coloured) and buffer (white) areas
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community observations and using a quantitative ac-
ceptability questionnaire before intervention and period-
ically throughout the monitoring year. To estimate the
cost-effectiveness of ITWL and LLINs vs. LLINs alone,
interviews will be conducted with residents who had a
malaria incident 30 days prior, to determine the direct
and indirect costs per malaria case. The cost of the inter-
vention will be the net cost of installing ITWL and cost of
malaria episodes in the study areas. The effectiveness will
be the number of malaria cases averted across the age
spectrum in the intervention areas, which will be assessed
by collecting supplementary data from an ‘older’ sub-set
Table 1 Timetable of study activities
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of participants (≥12 years old), and will be compared to
the control areas which only received LLINs.
A schematic representation of the trial is shown in Fig. 2.
Randomization and blinding
In cluster randomized controlled trials it is particularly
important to minimize imbalance for factors known to
be highly correlated with disease outcome, in this case
house construction/presence of open eaves and LLIN
usage. Since all households will be provided with LLINs
and the majority of homes have open eaves (89 % during
baseline surveys), clusters will be stratified into two groups
based solely on malaria prevalence; clusters in each stratum
will then be randomly assigned to the two study arms.
Stratified randomization of villages will reduce the likeli-
hood of chance imbalances between study arms but as only
a relatively small number of units can be randomized in
such a cluster design, both groups cannot be assumed com-
parable for all factors. Baseline data on malaria prevalence
and haemoglobin concentration collected from all enrolled
cohort participants will be used to assess disparity in dis-
ease burden at the village level prior to study monitoring.
Observer bias will be reduced where feasible; because
of the visible and obvious nature of the intervention, it
is not possible to conduct ITWL installation in a blinded
manner. Mosquito collector bias will be reduced by
using standard CDC miniature light traps and Furvela
tent traps, which do not rely on the technical ability of
the fieldworker to collect specimens. Trap catches will
be examined by a different person to the trap collector
and they will be blinded to the trap location and inter-
vention status. The intervention implementation, for
both ITWL installation and LLIN distribution, will be
monitored closely for quality and to document any bias
between the clusters. Epidemiological data entry will be
conducted using smartphones to minimize errors in col-
lection; GPS location and time of questionnaire adminis-
tration will also be recorded to ensure that interviews
Fig. 2 Schematic of study design
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are appropriately conducted and adequate time has been
devoted to data collection.
Loss to follow-up will be minimized through the use of
community health workers (CHWs) from each cluster to
ensure children are available during monthly study visits. In
the event of missing participants, the study team, assisted
by CHWs, will undertake home visits to locate cohort
members or may extend the monthly visits to each cluster
to sample participants who are temporarily unavailable.
Extended periods of time spent living away from a par-
ticipant’s cluster will be recorded and factored into the
analysis.
Study interventions
(a) Insecticidetreated wall lining (ITWL)
In the ITWL plus LLINs study arm, ITWL
installation will begin before the start of the short
rainy season in late August 2015. PermaNet®
Lining (Vestergaard Frandsen, Switzerland) is a
highdensity polypropylene fabric containing a
proprietary combination of two nonpyrethroid
insecticides (Fig. 3a), which is intended to mitigate
potential development of insecticide resistance.
One side of the fabric, designed to be attached
directly onto house walls, is UV and moisture
resistant, dust free and thermostable; the other
side, which faces the house interior contains the
insecticidal mixture incorporated into the polymer.
(b) Longlasting insecticidal nets (LLINs)
All LLINs distributed during this study will be
WHO-approved blue rectangular (160 cm wide x
180 cm long x 180 cm high) Interceptor® nets
(BASF Corporation, Germany), which contain
alphacypermethrin (200 mg/m2) coated onto
polyester fibres [41] (Fig. 3b).
Study intervention implementation
Prior to intervention implementation, a tiered and repeti-
tive approach will be taken to sensitize the community to
the objectives of the trial. Letters of introduction will be
sent to the District Medical Officer (DMO) and District
Executive Director of Muheza who will then introduce the
research team to the selected study villages. Meetings will
be held with these district officials, village-cluster and sub-
village leaders to inform them of the study, explain the
procedures and timelines and to address any questions or
concerns. Because new issues can arise at any point, study
staff will regularly attend community meetings throughout
the monitoring period to address any problems and to
provide an update of study progress.
Distribution of LLINs will be timed to occur shortly be-
fore ITWL installation in July-August, 2015, to ensure that
all study households are protected before the beginning of
the short rains and that participants are actively using
their LLINs prior to ITWL intervention. LLINs will be
distributed house-to-house, where one net will be given
per every two persons. House members will be given in-
structions on proper use and maintenance of nets by study
personnel.
ITWL installation is scheduled to begin in all buffer areas
in late August 2015, to allow study teams the opportunity
to remedy any unforeseen technical or logistical problems
before installation in core households. ITWL installation
will be rolled out in tandem with cohort recruitment. The
order in which intervention clusters will receive ITWL in-
stallations will be randomized; once all eligible cohort
members have been recruited in an intervention cluster
Fig. 3 a PermaNet® Lining. b Interceptor® LLINs
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and in a parallel randomly selected control cluster, ITWL
will be installed in all households in the core area of the
intervention cluster.
ITWL will be installed in each house by a three person
team. Each roll of ITWL is blue, measures approximately
2.4 m × 210 m, and will be cut to fit specific house or
room dimensions, recorded on the day of installation.
During installation, after all pieces of furniture are moved
into the centre of the room and wall items removed, the
team will work around the room fixing the ITWL to all
interior wall surfaces with nails at regular 60–70 cm inter-
vals; the material will be cut around doors and windows
and all eaves will be left uncovered. In houses with mul-
tiple rooms, ITWL will be installed in sleeping and living
areas only; kitchens, toilets and storage room walls will
remain bare. Educational material including information
about maintenance and cleaning of ITWL will be distrib-
uted to householders. The study team will not make any
formal repairs or install ITWL in new village houses once
the monitoring period has begun.
Clinical evaluations and patient treatment
Incidence of malaria parasitaemia (asymptomatic or
symptomatic) will be measured among the study cohort
monthly for 1 year by teams, each consisting of an expe-
rienced nurse or clinical officer and a CHW. Following
informed consent, at house-to-house enrollment, socio-
demographic and economic information, including age,
sex, education, sleeping habits, mosquito net use, house-
hold wealth, migration and health care-seeking behavior
will be collected using a standardized questionnaire. The
clinical team will initially assess each child for any severity
signs and referrals will be made for those with severe cri-
teria. Each child will then undergo a clinical assessment,
including a full medical history and physical examination
(weight, mid-arm circumference for children <5 years old,
height, respiratory rate, pallor and temperature), and blood
will be collected by finger-prick to perform an immediate
mRDT among all cohort members and to measure haemo-
globin concentration using a HemoCue® spectrophotometer
(AB Leo Diagnostics, Helsinborg, Sweden) in those aged 6
to 59 months.
At enrollment, all children will receive a curative weight-
appropriate three-day course of artemether-lumefantrine
(ALU), according to the Tanzanian National Treatment
Guidelines. Baseline treatment is intended to clear any
parasitaemia, irrespective of symptoms, considering recent
data suggest >50 % of malaria patients confirmed by PCR
are asymptomatic and negative by mRDT or microscopy
[42], and ALU provides a prophylactic effect, thus redu-
cing the likelihood that a cohort member will acquire
infection prior to the intervention. Adherence to the
first ALU dose will be observed by the study team at
enrollment and parents/guardians will be instructed to
administer the subsequent doses. Regimen completion
will be checked by CHWs and verified at the first month
visit by production of the empty drug packet. Families
whose children are enrolled will be issued an enumerated
identify card containing participant number and village
and the scheduled dates for subsequent visits.
Active monthly follow-ups will occur at village sentinel
sites. CHWs will be responsible for organizing village
leaders and parents in advance of the scheduled visit, in-
cluding arranging for school-aged children to be moni-
tored outside school hours. At each follow-up, the clinical
team will administer a physical examination, as described
above, and record a short medical history to assess recent
febrile illness, LLIN use and health care-seeking behav-
iour. A blood specimen will be collected by finger-prick
for an immediate mRDT; anaemia (moderate: haemoglo-
bin 7–8 g/dl to severe: haemoglobin <7 g/dl) will be mea-
sured in children aged 6 to 59 months at enrollment, at
6 months and 1 year post-intervention. In the case of a
positive mRDT, the child will receive a curative weight-
appropriate course of ALU, unless the child is already tak-
ing an appropriate antimalarial or has been within the past
2 weeks.
During the course of the study, the clinical team will
also provide treatment for non-malaria illnesses, including
paracetamol if axillary temperature is ≥37.5 °C, amoxicillin
for non-severe pneumonia, oral rehydration salts (ORS)
plus zinc for gastroenteritis and ferrous sulphate plus
albendazole for anaemia (haemoglobin <9 g/dl). Children
with severe illness at any time will be referred to Teule
district hospital for further management. Participants are
also free to receive medication from health personnel out-
side of the study teams.
Enrolled cohort children will be provided separate study
booklets that their parents or guardians will be instructed
to present each time that their child visits a health facility
during the follow-up period. The 24 health facilities serv-
ing the study area will be visited by the study teams prior
to the start of the study. Healthcare workers will be trained
to properly complete the study booklet for enrolled chil-
dren, recording whether the child was tested for malaria
either by microscopy or mRDT during the visit, the result
of the test, and what medication was prescribed or admin-
istered. During the monthly follow-up visits, study teams
will ask parents or guardians of enrolled cohort children
to present the study booklets, and any data on interim
health facility visits will be collected electronically. Parents
and guardians will also be asked to describe any other ill-
ness episodes that were not recorded in the study booklet.
Entomological evaluations
The primary entomological endpoint (EIR) will be mea-
sured using CDC miniature light traps in eight randomly
selected households with open eaves in 24 core cluster
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areas (12 clusters per study arm), every month (Table 1)
[43]. Eligible households will contain children enrolled
in the cohort study. In each household a CDC miniature
light trap will be positioned 50 cm away from a single
sleeper protected by a LLIN. To compare the extent of
outdoor biting and transmission, every other month Fur-
vela tent trapping will be undertaken in coordination with
indoor light trapping [44]. One tent will be used in each
cluster per night, set close to one of CDC light trapping
households. Indoor and outdoor mosquito collections will
be identified to species complex by microscopy [45] and
the numbers of An. gambiae s. l., An. funestus s. l. and
other Anopheles recorded. In each trap collection, a subset
of An. gambiae s. l. and An. funestus s. l. will be speciated
by PCR [46, 47]. In the case of An. gambiae s. l. knock-
down resistance status (presence of kdr L1014S or L1014F
alleles; previously kdr-east or kdr-west) will be determined
by PCR [48]. Plasmodium falciparum sporozoite infection
rates in An. gambiae s. s., An. arabiensis and An funestus
s. l. will be assayed using a circumsporozoite protein
(CSP) enzyme-linked immunosorbent assay (ELISA) [49].
To compare indoor mosquito resting density between the
two study arms, early morning pyrethrum spray catches
(PSCs) will be conducted in one household per cluster
(total of 48 households). PSCs will be performed before
intervention (during the long rainy season in May/June
2015), once during the cool dry season (August/Septem-
ber 2015) and during the second long rainy season (May/
June 2016) (Table 1). To determine host feeding prefer-
ences, all blood fed malaria vectors will be squashed and
dried onto filter papers and blood meal sources identified
by ELISA [50].
Insecticide resistance profiles in both study arms will
be compared before (during the long rainy season in
May/June 2015) and after intervention (during the sec-
ond long rainy season in May/June 2016) using three
different bioassays: WHO cylinder bioassays for resist-
ance to pyrethroids [51], CDC bottle bioassays for resist-
ance to the two non-pyrethroid ITWL active ingredients
[52] and resistance to pyrethroids. All assays will be
performed using locally collected field populations of
An. gambiae s. l. and An. funestus s. l. Larvae will be
collected by sampling multiple breeding sites from at
least six clusters per study arm, and reared to adults in
the NIMR insectary; all bioassays will be performed
using 2–5 day old unfed adult females.
Resistance to alphacypermethrin and permethrin will be
measured using WHO cylinders at standard diagnostic dos-
ages [53]. In lieu of WHO cylinder bioassays, CDC bottle
bioassays will be used to determine the 50 and 99 % lethal
doses (LD50 and LD99) to the two non-pyrethroid ITWL
active ingredients. To measure intensity of pyrethroid re-
sistance, the susceptible reference strain An. gambiae s. s.
Kisumu will be exposed to a range of alphacypermethrin
and permethrin dosages (0.001 μg/ml–0.5 μg/ml) to deter-
mine the LD50 [54]. A range of dosages will then be chosen
to test against wild collected adult An. gambiae s. l. and An.
funestus s. l (and F1 generations) that kill between 10 and
100 % before calculating the LD50 and comparing the resist-
ance ratios to the reference strain. The intensity of resist-
ance tests will be repeated on field collected specimens at
the end of each transmission season. For all WHO resist-
ance tests, six replicates of 20 mosquitoes and one control
replicate will be assayed and percent knockdown will be ob-
served every 15 min during 1 h of exposure; mortality will
be recorded after 24 h. Surviving and dead mosquitoes will
be analyzed for species identification and kdr resistance sta-
tus, as described above.
Intervention monitoring: ITWL
Prior to ITWL installation, quality control of the ITWL
material will be assessed using WHO cone [55] and modi-
fied WHO cylinder bioassays [51] from a random sample
of four rolls from each of five production lots (20 rolls
total). From each ITWL roll, three 25 × 25 cm squares will
be cut from a 2.5 × 1 m section for testing. Four WHO
cone assays will be tested per ITWL sample for a total of
12 cone assays per roll. WHO cones will be fixed to the
ITWL sample with frames and ten 2–5 day old unfed sus-
ceptible An. gambiae s. s. Kisumu mosquitoes or wild col-
lected adult An. gambiae s. l will be exposed for 30 min;
knockdown will be recorded after 1 h and mortality after
24, 48 and 72 h; the same experimental conditions will be
used for WHO cylinder bioassays.
ITWL durability surveys will be conducted in 5 ran-
domly selected households from eight intervention clus-
ters (total of 40 households) at three, six and 12 months
after intervention. At each follow-up, interviewers will
survey the house to evaluate the condition of the ITWL
installation and to record failed fixings, material tearing,
causes of damage, proportion of walls still covered with
ITWL and any evidence of ITWL repair, maintenance or
attrition. In the same houses, ITWL in situ bioefficacy
will be assessed using five WHO cone bioassays con-
ducted as described above, at two wall heights (<1 m
and >1 m from the floor) for a total of 10 bioassays per
house. In addition, 5 × 5 cm samples of ITWL will be
cut from house walls and insecticide content measured
using HPLC according to the Collaborative International
Pesticides Analytical Council (CIPAC) protocol.
Intervention monitoring: LLINs
As part of the standardized questionnaire administered dur-
ing each monthly cohort follow-up, LLIN coverage, use and
attrition will be monitored. Participants will be asked about
number of LLINs owned and number of sleeping places
covered at the household level using a modified version of
the WHO LLIN durability questionnaire [56].
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Social acceptability and economic evaluations
To identify social, cultural and other factors that may
affect acceptability and uptake of ITWL and LLINs in the
study area, a series of FGDs and IDIs will be undertaken.
Four FGDs will be conducted in two randomly selected
villages from each study arm prior to intervention and in
the same villages after ITWL installation and LLIN distri-
bution (total of 16 FGDs). FGDs will be conducted with
small groups (8–12 participants) of men and women sep-
arately to reflect the different roles played in Tanzanian
society and to ensure that all members will feel able to
contribute to the discussion. In each village, one FGD will
comprise heads of households and the other mothers of
children <5 and mothers of children aged 5 to 11 years
old. FGDs will be led by a trained moderator who will
use a guide with open-ended questions to explore with
the group a series of broad topics relating to malaria,
disease prevention, ITWL concept and installation,
LLIN use and healthcare seeking behavior and access.
FGDs will be digitally recorded with consent from par-
ticipants and a note-taker will document all non-verbal
communications.
IDIs will be conducted with village or hamlet leaders,
CHWs from village health facilities and ITWL installers to
explore the opinions of key individuals who may play im-
portant roles in influencing community members’ percep-
tions of ITWL and LLIN use. Four IDIs will be conducted
per study arm prior to intervention and with the same in-
dividuals after ITWL installation and LLIN distribution
(total of 16 IDIs). The IDIs will cover a range of similar
topics to the FGDs. IDIs will be conducted by a trained
interviewer and digitally recorded with participant’s con-
sent; non-verbal communication will be documented by
hand. Informal community observations relating to major
study activities, including community sensitization meet-
ings, ITWL installation and LLIN distribution, will also be
recorded by the study teams. Following the FGDs and
IDIs, the main themes identified will be used to design
a standardized, closed-ended quantitative acceptability
questionnaire to be administered at three, six and
12 months post-intervention.
To assess the cost-effectiveness of ITWL + LLINs vs.
LLINs alone, supplementary data will be collected from
an additional ‘older’ sub-set of participants (≥12 years
old) who occupy the same households as members of
the main study cohort. From the baseline census, it is
estimated that the 110 children/core area will represent
70 households and each core household will contain an
average of three ‘older’ individuals. To determine the
incremental effectiveness of ITWL across the entire age
spectrum, during monthly cohort follow-ups, the key
informant will report whether within the preceding
30 days, any ‘older’ household member(s) experienced a
febrile illness and what, if any, treatment was received;
if the informant themselves report a febrile illness, they
will be asked to be tested with an mRDT immediately.
To estimate the economic cost per malaria episode,
macro-cost analysis of hospital statistics from Teule
Hospital and Mkuzi Health Centre (Muheza’s only dis-
trict hospital and major health centre, respectively) will
be used to determine the medical costs (cost per bed day
and per outpatient visit) associated with an episode of
clinical malaria and a household economic survey will
measure additional out-of-pocket expenditures associ-
ated with care-seeking, non-medical direct and indirect
costs and the impact of malaria on household food se-
curity. The economic questionnaire will be conducted
on a monthly basis among all hospitalized cases, identi-
fied during the cohort visits, and an additional, randomly
selected 14 % of households containing cohort children,
to detect malaria cases treated in other settings (e.g. am-
bulatory, treated at home or with no treatment). During
the economic questionnaire, all household members
who report a febrile illness during the preceding 30 days
will be interviewed and if they were not tested for malaria,
they will be asked to take an mRDT; for children under
18 years old, the mother will be interviewed on their be-
half. Any reduction in malaria-related school absenteeism
by cluster will be measured during the monthly cohort
visits, relative to the number of days two local schools was
operational (verified by trusted community leaders and/or
head teachers).
To measure the cost of LLINs distribution and ITWL in-
stallation, a micro-costing or ingredient approach to deter-
mine the personnel effort and materials, and a top-down
costing approach to estimate the indirect cost associ-
ated management, oversight, transportation, and moni-
toring will be used. Additional meta-data on the cost of
IRS implementation in other Tanzanian districts will be
provided by Research Triangle Institute (RTI) and re-
cently published estimates of the effectiveness of IRS in
combination with LLINs [5], will be compared with the
cost-effectiveness of ITWL.
Trial oversight, safety considerations and handling
withdrawals/drop-outs
Trial oversight will be provided by a Data and Safety Mon-
itoring Board (DSMB) comprising three independent clin-
ical and epidemiological experts. The role of the DSMB is
to safeguard the interests of study participants as well as
assess the safety and effectiveness of the study interven-
tions. Independent data reviews by the DSMB will be con-
ducted every 3 months throughout the study year.
Any adverse events (AEs) arising from either LLINs or
ITWL will be closely monitored and documented. Inter-
ceptor® LLINs have been fully evaluated by the WHO
Pesticide Evaluation Scheme (WHOPES) and approved for
vector control; the product will be used in compliance with
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their recommended guidelines [57]. The non-pyrethroid
insecticides in the ITWL have low mammalian toxicity and
good safety profiles [58]. The proprietary combination
formula used in the ITWLs has passed an initial environ-
mental examination (IEE) conducted by an independent
regulatory agency; hazard quotients for continuous habita-
tion in a residence with ITWL were far below the accept-
able threshold. All ITWL installers, who will receive the
highest levels of exposure, will wear personal protective
equipment (PPE; a minimum of gloves, long sleeves and
eye protection) during intervention implementation. ITWL
installers will undergo pre-installation, mid-way and post-
installation medical examinations, which will include mon-
itoring for any AEs.
During the ITWL intervention period, all core and buf-
fer households will be visited 6–10 days following installa-
tion to document any AEs. Adverse event monitoring will
also occur among ITWL installers through a passive AE
monitoring chain. Throughout the study year, AEs will be
monitored actively in each monthly cohort follow-up visit,
during which the clinical team will ask the parents of co-
hort participants to report all AEs for any members of
their household. Cohort members will also be given a
study card to take to local health facilities, which will be
used to record any AEs arising between monthly study
visits. Other study participants will report AEs at any
point to the CHWs, health facility or study team through
a passive AE monitoring chain in both core and buffer
areas. All AEs such as skin or eye irritation, respiratory
problems, dizziness, nausea etc., will be graded in terms of
severity (mild, moderate or severe), seriousness (based on
patient outcome) and relatedness to the intervention by
comparison with the control arm [58]. Appropriate man-
agement for any AE will be provided according to local
guidelines and the outcome of AEs, including resolution,
persistent disability, birth defect or death will be recorded.
In the case of a serious adverse event (SAE), the study
clinician will record and manage the SAE in accordance
with Good Clinical Practice (GCP) and report these to
the PI who will inform the responsible member of the
trial DSMB. Excessive grouping of SAEs by village or
cluster will be reported to the DSMB and respective in-
stitutional ethics committees. A determination by the
DSMB that there is potential harm to participants or the
environment caused by the interventions will result in
discontinuation of the study.
If an individual or household wants to terminate their
participation, no further follow-up will be performed. If
a cohort participant misses three consecutive monthly
follow-up visits, they will be excluded from the study
analysis. There will be no participant replacement dur-
ing the surveillance period. If a household withdraws
that was participating in the durability monitoring, it
will be substituted with a neighbouring house of similar
construction, where possible; there will be no other
household or village replacements.
Study endpoints
Epidemiological
Primary endpoint: the cumulative incidence of malaria
parasitaemia (asymptomatic and symptomatic) defined
as the number of mRDT-confirmed episodes of parasit-
aemia per child per year. A child will be considered to
have experienced an episode of parasitaemia during a
given month if they had a positive mRDT during the
scheduled monthly follow-up visit, irrespective of symp-
toms. Two consecutive positive scheduled mRDT results
will be treated as two separate episodes and any malaria
cases diagnosed and treated at health facilities between
monthly visits will also be counted as episodes.
Secondary endpoints: (i) time to first episode of mal-
aria parasitaemia (asymptomatic and symptomatic) as
determined by mRDT as per the primary case definition;
(ii) changes in mean levels of haemoglobin among co-
hort children aged 6 to 59 months.
All study outcomes will be compared between the inter-
vention (ITWL+LLINs) and the control arm (LLINs only).
Entomological
Transmission parameters in the two study arms will be
estimated from measurements made throughout the
transmission season.
Primary endpoint: the EIR for An. gambiae s. l. and
An. funestus s. l. estimated as the mean number of
sporozoite infective bites/person/year.
Secondary endpoints: (i) the relative abundance of
outdoor host-seeking An. gambiae s. l. and An. funes-
tus; (ii) host feeding preferences of An. gambiae s. l.;
(iii) changes in frequency (% mortality using diagnostic
dose) and strength (LD50 and resistance ratio) of in-
secticide resistance to alphacypermethrin, permethrin,
non-pyrethroid insecticides in each study arm; (iv)
ITWL bioefficacy and durability over 12 months.
Sample size rationale
Epidemiological
LLINs can reduce malaria morbidity by approximately
40–70 % [3]; the impact of ITWL alone or in combin-
ation with LLINs on malaria is unknown. The effects
may be additive or synergistic (e.g. by having a mass kill-
ing effect and/or reducing mosquito longevity) or antag-
onistic (e.g. if the LLINs are repellent thereby reducing
mosquito house entry and contact with ITWL). Due to
the intensity and projected cost of the ITWL interven-
tion, a minimum reduction in malaria of 30 % is consid-
ered of public health importance.
For the cohort study, sample size is based on annual
cumulative incidence of malaria infection in each study
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arm as the primary outcome. From baseline surveys con-
ducted in Muheza, it was assumed that cumulative inci-
dence of malaria would be 2.5–3.0 detected episodes/year,
with a coefficient of variation (CV) between clusters of
0.302 and an intra-cluster correlation (ICC) of 0.047.
Therefore with 22 clusters per arm, sampling an average of
110 children (assuming 18 % loss to follow-up) per cluster,
the study will have >85 % power to detect a 30 % reduction
in malaria incidence at the 5 % significance level [59].
To measure time to first malaria episode during the
evaluation year, assuming an ICC of 0.047, for a cumulative
incidence of 2.0 episodes/year, the monthly risk would be
0.167. Using a binomial distribution calculation, the prob-
ability of having zero positive determinations (i.e. of ‘sur-
viving’ malaria-free) over 1 year is (1–0.167)12 = 0.112; with
a monthly 30 % reduction in risk, the cumulative probabil-
ity of having no monthly positive RDTs in 12 months in
the intervention arm would be (1–0.117)12 = 0.226. Sam-
pling from 44 clusters with 90 children per cluster, the
study will have 99 % power to reject the null hypothesis of
no difference in ‘survival’.
To assess the effectiveness of the interventions on an-
aemia in children aged 6 to 59 months, assuming mean
haemoglobin of 10.75 g/dl, 22 clusters in each study
arm and a CV of 0.048, the study will be able to detect
a difference of 0.5 g/dl in mean haemoglobin with 5 %
significance and 85 % power between the study arms,
sampling an average of 45 children per cluster.
Entomological
Monitoring of indoor mosquito density will be con-
ducted bi-monthly in eight different randomly selected
households from six clusters per study arms (total of
576 households). All anopheline mosquitoes from each
household will be randomly chosen for analysis (speci-
ation, sporozoite ELISA, kdr resistance status and blood
meal source).
Data handling and record keeping
All demographic and clinical data will be collected on An-
droid smartphones containing pre-programmed, pre-
tested, standardized data entry forms, and sent directly to
an electronic server. Each cohort member will have a
unique identification number (ID) and non-cohort partici-
pants will be identified by a demographic enumeration
number. All forms and datasets will record participants
using these codes; no personal identifiers will be entered.
All data computers will be password protected with re-
stricted access to only authorized study investigators and
data management staff; field workers will have no access
to the server. Daily data checks will be performed to
identify incomplete, missing, inaccurate or inconsistent
data, which will be rectified by the appropriate study in-
vestigator. Clinical data will be kept separately from that
containing personal information. Data will be stored for
at least 10 years.
The PI will maintain appropriate medical and research
records in compliance with GCP and regulatory and in-
stitutional requirements. Authorized representatives of
the sponsor, the ethics committee(s), the DSMB or other
regulatory bodies may inspect all documents and records
at any time. The PI will ensure access to facilities and re-
cords, as required.
Data analysis
All statistical analyses will be performed using STATA ver-
sion 13 (StataCorp LP, College Station, TX, USA). The pri-
mary endpoint will be a comparison of the cumulative
incidence of symptomatic or asymptomatic episodes of
malaria in children between the two intervention groups.
Data from cohort members who are lost to follow-up or
who missed monthly visit(s) will be treated as censored.
Similarly, children who are taking anti-malarial drugs,
based on a positive mRDT, will be excluded in the analysis
for the first 2 weeks following treatment. History of travel
away from the study village will be recorded during
monthly visits and time at risk will be censored for such
periods. In addition, malaria cases in children who resided
outside their cluster area for more than half of the elapsed
study period at the time of illness will be excluded.
An initial analysis will compare the cumulative malaria
incidence rates between the two study arms to assess the
number of episodes of malaria parasitaemia (symptom-
atic, asymptomatic or combined) per child per year. A
follow-up analysis will examine the time to first episode
of clinical malaria. The rate ratio (RR) will be calculated
by dividing the incidence rate in the intervention relative
to the control arm. The effectiveness of ITWL + LLINs
vs. LLINs alone will be obtained from the final analysis
as 1-RR. Cox regression modeling will be used to investi-
gate potential confounding such as season and age. A
priori confounders will be included in the model and
that the presence of effect modification or interaction
terms will be explored. Both intention to treat (all per-
sons randomized) and per protocol analyses (all persons
who received the intervention) will be conducted. All
analyses will be adjusted for within-cluster correlation
using generalized estimating equations or random effects
models with gamma frailty. In addition, missing data will
be analyzed and multiple imputation used, if required.
Similarly, mean haemoglobin in 6–59 month olds will
be measured and compared between the two arms.
Other outcome variables, including entomological indi-
ces, cost-effectiveness and acceptability of interventions
will be compared between study arms accounting for any
correlated observations within clusters or households.
Digitally recorded FGDs and IDIs will be transcribed
and translated verbatim and the data analysis procedure
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will follow a bottom-up approach by coding the raw data
line-byline. The coding will be done by two research
assistants to ensure intercoder reliability. Themes and
theoretical constructs will emerge and will be grouped
together as per the objectives. This method reflects a
more analytical approach and will borrow the iterative ap-
proach of grounded theory analysis [60]. Data will be or-
ganized by importing into new QSR Nvivo 10 workbook
and filed into the ‘internals’ section. Transcripts will be
coded in an ongoing process as data is collected whereby
a coding template will be developed from initial tran-
scripts. As more data is received and coded, the template
will be further refined to reflect any new emerging ideas
or themes. These will appear in Nvivo as nodes which will
be arranged in groups under a parent node labeled with
the theme. Beyond this, themes may be organized into
wider groups representing theoretical constructs. Memos
will be made to explain the justification behind forming
the construct. The social scientists from the project to-
gether with the wider research team will develop a nar-
rative linking the original research objectives with the
participants’ subjective practices and experiences. The
aim of these theoretical descriptions will be to reiterate
the participants’ narratives in terms of the theoretical
constructs.
Quantitative data derived from household acceptability
questionnaires will be compared using appropriate sum-
mary statistics, such as mean differences and proportions.
All exposure variables showing evidence of relationships
with acceptability of the study intervention in univariate
analysis will be fitted in a multivariable logistic regression
model. A stepwise backwards strategy will be used to
eliminate variables with no effect (p > 0.05), these multi-
level models will adjust for clustering within village or
household and investigate for possible confounding or
interaction.
Economic data collected will be used to assess the dir-
ect and indirect costs per malaria episode averted in
each study arm.
Discussion
The future of malaria control in Sub-Saharan Africa is
threatened by problems of consistent use, sustainability
and the rapid expansion of pyrethroid-resistant vector pop-
ulations. While reductions in disease burden achieved by
LLINs and IRS are irrefutable, the development of novel
vector control strategies and insecticide delivery mecha-
nisms will be crucial to maintain gains and facilitate the
movement towards malaria elimination and eradication.
This is the largest cluster randomized controlled trial to
evaluate whether non-pyrethroid ITWL can provide add-
itional protection against clinical malaria compared to the
current best practice of UC with LLINs. The potential lon-
ger lifespan and residual activity of ITWL, the absence of
repeated intervention costs, and community-wide effect
may render ITWL a superior control technique to LLINs
alone. ITWL is expected to deter indoor human biting
and decrease mosquito longevity and abundance; together
these effects should reduce malaria transmission intensity.
Furthermore, the use of two non-pyrethroid insecticides
over time may lead to partial reversal of the frequency and
intensity of pyrethroid resistance among local vector pop-
ulations [61].
The operational success of ITWL will be determined
not only by its demonstrable protective efficacy but also
its feasibility of implementation, levels of household ac-
ceptability, durability under field conditions and cost-
effectiveness compared to other first-line strategies. This
trial will investigate the effectiveness of ITWL in a ‘real-
to-life’ community setting and aims to establish a prece-
dent in multidisciplinary evaluations of new large-scale
control interventions.
If ITWL is proven both effective, durable and feasible, it
may warrant consideration for programmatic implementa-
tion. How ITWL would be executed to scale and in which
particular epidemiological situations will depend on its
relative cost-effectiveness compared to other main-line
strategies (IRS and LLINs). ITWL is unlikely to super-
sede IRS as part of routine malaria control, but may
have an important role to play as a mechanism of house
improvement [62–64]. Alternatively, ITWL could serve as
a complementary strategy for use in endemic transmission
settings, particularly in areas where pyrethroid-resistant
vectors predominate, or in regions moving towards
malaria elimination [65, 66]. Trial findings will provide
valuable information for the National Malaria Control
Programme (NMCP) and policy makers in Tanzania
and other malaria-endemic countries to guide finite re-
source allocations for future control efforts.
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